Actively Recruiting
Study of Furmonertinib 160mg as First Treatment for Advanced or Metastatic Non-small Cell Lung Cancer with EGFR Mutations
Led by Peking Union Medical College Hospital · Updated on 2024-11-05
144
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of furmonertinib as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer NSCLC who have specific EGFR mutations known as 19Del or L858R. This Phase 3 clinical trial aims to assess the drugs effect on progression-free survival, tumor response rates, overall survival, and central nervous system outcomes, as well as its safety and patterns of disease recurrence and resistance. Participants will receive furmonertinib orally at a dose of 160mg once daily. This study does not include a comparison group and focuses on the outcomes of this single treatment regimen. The treatment period and follow-up assessments are structured to monitor patients for approximately 24 months after starting therapy, with evaluations of tumor response and disease control occurring at specified intervals. During the study, participants will undergo regular scans and laboratory tests to measure tumor size, disease progression, and overall health. Researchers will track side effects and adverse events from the start of treatment until 28 days after the last dose. The main outcome measured is progression-free survival, with other important outcomes including overall survival and central nervous system response. The study includes ongoing safety monitoring and aims to understand how the cancer may recur or develop resistance to treatment over time.
CONDITIONS
Brief Title
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here